These results suggest that GJs (GJ1–GJ4) alleviate the symptoms of DSS-induced colitis by inhibiting the expression of inflammatory cytokines and mediators via NF-κB activation and the MAPK signaling pathway. The gene discussed is NFKB1; the disease is colitis.